Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis

• Published in: PloS one Vol. 13; no. 9; p. e0203767
• Main Authors: Wetmore, James B, Li, Suying, Yan, Heng, Xu, Hairong, Peng, Yi, Sinsakul, Marvin V, Liu, Jiannong, Gilbertson, David T
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 26.09.2018; Public Library of Science (PLoS)
• Subjects: Analysis; Anemia; Biology and Life Sciences; Cardiovascular diseases; Care and treatment; Choirs; Chronic illnesses; Cohort analysis; Dialysis; End-stage renal disease; Engineering and Technology; Erythropoiesis; Hazards; Hematinics; Hemodialysis; Hemoglobin; Kidney diseases; Medical research; Medicare; Medicine and Health Sciences; Mortality; Outcome and process assessment (Medical care); Patients; Peritoneal dialysis; Prospective payment systems; Social Sciences; Statistical models; Systematic review; United States > US; Maryland; Minnesota
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0203767

Whether and how anemia treatment with erythropoiesis stimulating agents (ESAs) before hemodialysis initiation may be associated with lower mortality after dialysis initiation is unknown. We compared all-cause and cardiovascular mortality in two groups of patients who experienced distinct anemia treatment patterns with ESAs before and after hemodialysis initiation. This retrospective cohort analysis included patients initiating hemodialysis April 1, 2012-June 30, 2013, identified from United States Renal Data System end-stage renal disease (ESRD) and pre-ESRD files. Patients treated with ESAs before and after hemodialysis initiation who maintained Hb ≥ 9.0 g/dL throughout (comparator group, n = 3662) were compared with patients with Hb < 9.0 g/dL before hemodialysis initiation (with or without ESAs) whose levels increased with ESAs after hemodialysis initiation (referent group, n = 4461). Cox proportional hazards models were used to calculate the hazard ratio of all-cause and cardiovascular mortality after hemodialysis initiation. Of 20,454 patients, 4855 (23.7%) had Hb < 9.0 g/dL upon hemodialysis initiation; of these 4855, 26.6% received ESAs before initiation. Comparator group Hb levels increased from 8.2 ± 0.8 mg/dL upon initiation to 10.9 ± 1.2 with ESAs afterward. Comparator patients were more likely than referent patients to be younger (76.3 ± 6.7 versus 77.2 ± 6.9 years), male (51.5% versus 49.8%), and black (24.6% versus 18.6%). Risk of all-cause mortality was lower for the comparator group versus the referent group at 3 (HR 0.83, 95% CI 0.68-1.00, P = 0.052), 6 (0.86, 0.74-1.00, P = 0.047), and 12 (0.88, 0.78-0.99, P = 0.036) months. The pattern was similar for cardiovascular mortality. Hb ≥ 9.0 with ESAs before and after hemodialysis initiation was generally associated with lower post-initiation all-cause and cardiovascular mortality compared with predialysis Hb < 9.0 g/dL in patients whose Hb levels subsequently improved with ESAs after hemodialysis initiation.